Contact information
ester.hammond@oncology.ox.ac.uk
+44 (0)1865 617320
Follow the Hammond Lab on Bluesky - @Hammond-lab.bsky.social
Research groups
Research Theme
Tumour Microenvironment (Lead Principal Investigator)
Websites
-
HIT-GLIO
HORIZON funded consortium
-
RadNet seminar by Prof. Hammond
Watch on YouTube
Colleges
Ester Hammond
Professor of Molecular Cancer Biology
- TME Research Theme lead, Department of Oncology
- Academic lead for Department of Oncology Pathways to Academic Independence (PAI) programme
Research Summary
We investigate how tumours survive in conditions which include low oxygen (hypoxia). The goal is to target the hypoxic parts of tumours to improve cancer therapy.
Biography
Ester completed her PhD at the School for Cancer Sciences, University of Birmingham then accepted a post as a postdoctoral fellow within the Molecular Oncology Group at the University of Cambridge School of Clinical Medicine before moving to the USA to join the Department of Radiation Oncology at Stanford University, first as a postdoctoral fellow then a research associate. She joined the Department in 2007.
Join Us
Funded DPhil Project: Investigating changes in RNA-binding proteins in hypoxia as a means of increasing radiosensitivity
Postdoctoral Research position available: Hypoxia in paediatric high-grade gliomas
GROUP MEMBERS
Recent publications
-
High-Affinity Peptide-Drug Conjugate Ligands for the TRIM24 PHD and Bromodomain.
Journal article
Platt MA. et al, (2025), Chemistry, 31
-
Immunopeptidomics Workflow for Isolation and LC-MS/MS Analysis of MHC Class I-Bound Peptides Under Hypoxic Conditions.
Journal article
Estephan H. et al, (2025), Bio Protoc, 15
-
A guide to reactive oxygen species in tumour hypoxia: measurement and therapeutic implications.
Journal article
Hacker L. et al, (2025), Mol Oncol, 19, 3003 - 3022
-
Reversible Enzymatic Switching of the Oxidation State of a EuIII/II Complex Controls Relaxivity.
Journal article
Sarson ET. et al, (2025), J Am Chem Soc, 147, 38992 - 38997
-
Identification of a photoredox-active Pt(IV) complex that induces light-mediated cell death.
Journal article
Marsh JW. et al, (2025), Chem Sci, 16, 19187 - 19191
-
Indolequinone-Based Hypoxia-Activated Proteolysis Targeting Chimeras Selectively Degrade BRD4 in Hypoxic Cancer Cells.
Journal article
Serafini M. et al, (2025), J Am Chem Soc, 147, 36352 - 36364

